| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Brendan Smith maintains Novavax (NASDAQ:NVAX) with a Hold and lowers the price target from $8 to $7.
SEC
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...
https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax (NASDAQ:NVAX) with a Overweight rating and announc...
HC Wainwright & Co. analyst Sean Lee maintains Novavax (NASDAQ:NVAX) with a Buy and raises the price target from $10 to ...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
- SEC 13D/ Amended Filing